1 October 2024 - Non-profit health plan collaborates with Fresenius Kabi and Evio Pharmacy Solutions to purchase FDA approved Humira biosimilar ...
26 September 2024 - The EMA’s CHMP has recommended suspending the marketing authorisation for the sickle cell disease medicine Oxbryta ...
25 September 2024 - Pfizer announced today that it is voluntarily withdrawing all lots of Oxbryta (voxelotor) for the treatment of ...
24 September 2024 - Amgen today announced Tepezza (teprotumumab) has been approved for the treatment of active or high clinical activity ...
25 September 2024 - First regulatory authorisation of a CRISPR-based gene-editing therapy in Canada. ...
24 September 2024 - Omicron KP.2 variant adapted vaccine Comirnaty is now authorised in Canada for individuals 6 months of age ...
17 September 2024 - Spikevax is the first updated COVID-19 vaccine authorised in Canada for 2024-2025, offering a timely solution to ...
24 September 2024 - Today, the US FDA approved Aqneursa (levacetylleucine) for the treatment of neurological symptoms associated with Niemann-Pick disease ...
25 September 2024 - Today, the FDA approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for adult patients with locally advanced, unresectable (stage ...
25 September 2024 - NICE has published final evidence-based recommendations on the use of trifluridine with tipiracil hydrochloride (Lonsurf) for ...
20 September 2024 - An appeals court revived the case and sent it back to a lower court in Texas. ...
24 September 2024 - Marketing authorisation in EU expected by November 2024. ...
24 September 2024 - Santhera Pharmaceuticals announces that Swissmedic, the Swiss Agency for Therapeutic Products, has accepted for review the ...
24 September 2024 - Japan is the second major market where Kisunla has received approval. ...
24 September 2024 - Approval based on results from positive, global, Phase 3 FRESCO-2 trial. ...
24 September 2024 - US FDA has set a PDUFA target action date of 22 May 2025. ...